What is Bifidobacterium lactis DSM 15954?

Based on publicly available information, the Bifidobacterium lactis DSM 15954 strain is genetically identical to the more commonly known strain Bifidobacterium lactis BB-12®¹.

BB-12® is one of the most extensively studied probiotic strains worldwide². First isolated in the 1980s, it had already been investigated in more than 130 human clinical trials by 2014³, and more recent summaries indicate that the number of studies now exceeds 200⁴.

A distinctive feature of BB-12® is its ability to produce acetate and lactate, compounds that help shape the gut environment by lowering pH and providing fuel for other beneficial microbes⁵. It is also a naturally occurring member of the infant gut microbiome, particularly in breastfed babies³.

Scientific Research: BB-12

BB-12® has been studied in human trials investigating areas such as bowel regularity, constipation, diarrhoea, and immunity. Research consistently demonstrates its excellent safety profile across a wide range of groups, including preterm babies, infants and older adults. You can explore a selection of these publications in our research library.

Where You’ll Find It

BB-12® has been widely used in infant formulas, dietary supplements, and fermented milk products across the world. However, in multi-strain supplements it is often included at a dose lower than the dose studied in the clinical trials.

At Evidose, we include Bifidobacterium lactis DSM 15954 (identical to BB-12®) in our Live Biotic Daily+ formula, at a dose consistent with those used in published research.